Target RWE

Acquired by Highlander Health in January 2025, Target RWE generates complete, longitudinal datasets with the power of advanced analytics and rigorous causal inference methodologies to uncover deep insights on unmet needs, disease progression, and the efficacy and safety of new treatments in the real world. With strong expertise in liver disease, gastroenterology, and dermatology, Target RWE’s multi-stakeholder model allows you to develop robust disease protocols to inform study objectives and endpoints. Our registries contain all relevant disease state variables, which when combined with our digital collection of patient and clinician reported outcomes and biosamples provide a framework for decisions on study entry criteria and site selection – reducing unnecessary procedures and costly protocol amendments.